Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: A scoping review

Neurourology and Urodynamics

Volumn 30, Issue 4, 2011, Pages 490-494

  Hunter, Kathleen F ^a   Wagg, Adrian ^a,c   Kerridge, Teresa ^a   Chick, Hope ^b   Chambers, Thane ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

antimuscarnic; falls; falls risk; overactive bladder

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE;

ARTICLE; COGNITIVE DEFECT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FALL RISK; FALL RISK ASSESSMENT; HIGH RISK PATIENT; HUMAN; OVERACTIVE BLADDER; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; URGE INCONTINENCE;

ACCIDENTAL FALLS; HUMANS; MUSCARINIC ANTAGONISTS; RISK; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 79954603510     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21051     Document Type: Article

References (32)

1. Abrams P, Andersson KE,. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006. (Pubitemid 47537675)
2. Serels S,. The wet patient: Understanding patients with overactive bladder and incontinence. Curr Med Res Opin 2004; 20: 791-801. (Pubitemid 38821515)
3. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6. (Pubitemid 34204313)
4. Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology 2010; 532: 526-32.
5. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36. (Pubitemid 44175300)
6. Asplund R,. Pharmacotherapy for nocturia in the elderly patient. Drugs Aging 2007; 24: 325-43. (Pubitemid 46625652)
7. Haab F, Castro-Diaz D,. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 2005; 59: 931-7.
8. Bulat T, Castle SC, Rutledge M, et al. Clinical practice algorithms: Medication management to reduce fall risk in the elderly-part 4, anticoagulants, anticonvulsants, anticholinergics/bladder relaxants, and antipsychotics. J Am Acad Nurse Pract 2008; 20: 181-90.
9. Morris V, Wagg A,. Lower urinary tract symptoms, incontinence and falls in elderly people: Time for an intervention study. Int J Clin Pract 2007; 61: 320-3.
10. Pappano A,. Chapter 8: Cholinoreceptor-blocking drugs. In:, Katzung B, editor. Basic and clinical pharmacology, 10th edition. New York, NY: The McGraw-Hill Companies, Inc.; 2007. p. 108-20.
11. Hay-Smith J, Herbison P, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005; 3: 005429. DOl: 10. 1002/14651858.CD005429.
12. Potter W, Hollister L,. Antidepressant agents. In:, Katzung B, editor. Basic and clinical pharmacology, 10th edition. New York, NY: McGraw-Hill Companies, Inc.; 2007. p. 475-89.
13. Schliebs R, Arendt T,. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 2006; 113: 1625-44. (Pubitemid 44657659)
14. Kay GG, Ebinger U,. Preserving cognitive function for patients with overactive bladder: Evidence for a differential effect with darifenacin. Int J Clin Pract 2008; 62: 1792-800.
15. Olson KR,. Chapter 59: Management of the poisoned patient. In:, Katzung B, editor. Basic and clinical pharmacology, 10th edition. New York, NY: The McGraw-Hill Companies, Inc.; 2007. p. 958-70.
16. Han L, Agostini JV, Allore HG,. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56: 2203-10.
17. Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Arch Intern Med 2009; 169: 1317-24.
18. Tune LE,. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001; 62: 11-4. (Pubitemid 32937572)
19. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: Relationship with cognitive performance. Arch Gen Psychiatry 2003; 60: 198-203. (Pubitemid 36173127)
20. Nebes RD, Pollock BG, Halligan EM, et al. Serum anticholinergic activity and motor performance in elderly persons. J Gerontol A Biol Sci Med Sci 2007; 62: 83-5. (Pubitemid 46931552)
21. Kay GG, Abou-Donia MB, Messer WS, Jr., et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53: 2195-201. (Pubitemid 43001205)
22. Grant MJ, Booth A,. A typology of reviews: An analysis of 14 review types and associated methodologies. Health Info Libr J 2009; 26: 91-108.
23. Arksey H, O'Malley L,. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol 2005; 8: 19-32. (Pubitemid 40322704)
24. Mays N, Roberts E, Popay J,. Synthesising research evidence. In:, Fulop N, Allen P, Clarke A, Black N, editors. Studying the organisation and delivery of health services. Routledge: Research Methods London; 2001. p. 188-220.
25. Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008; 56: 862-70. (Pubitemid 351652413)
26. van der Velde N, Stricker BH, Pols HA, et al. Risk of falls after withdrawal of fall-risk-increasing drugs: A prospective cohort study. Br J Clin Pharmacol 2007; 63: 232-7. (Pubitemid 46072110)
27. van der Velde N, Meerding WJ, Looman CW, et al. Cost effectiveness of withdrawal of fall-risk-increasing drugs in geriatric outpatients. Drugs Aging 2008; 25: 521-9. (Pubitemid 351812259)
28. Kallin K, Lundin-Olsson L, Jensen J, et al. precipitating factors for falls among older people in residential care. Public Health 2002; 116: 263-71.
29. Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-13. (Pubitemid 351547214)
30. Ziere G, Dieleman JP, Hofman A, et al. falls in the middle age and elderly population. Br J Clin Pharmacol 2006; 61: 218-23. (Pubitemid 43382615)
31. Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients >or= 65 years with overactive bladder: Results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007; 23: 2347-58. (Pubitemid 350033436)
32. Wesnes KA, Edgar C, Tretter RN, et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009; 8: 615-26.